Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Amneal Pharmaceuticals Inc (NY: AMRX )

4.850 USD -0.120 (-2.41%)
Official Closing Price Updated: 7:36 PM EST, Jan 25, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Amneal Pharmaceuticals Inc

< Previous 1 2 3 Next >
Amneal to Acquire Substantially All of Kashiv Specialty Pharmaceuticals
Amneal Pharmaceuticals, Inc. (the “Company”) (NYSE:AMRX) and Kashiv BioSciences LLC (“Kashiv”) today announced they have entered into a definitive agreement under which Amneal Pharmaceuticals LLC... 
From Business Wire News Releases
Amneal Launches Generic Abiraterone Acetate Tablets, USP, 500 mg, Following ANDA Approval by FDA
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) announced that it has received approval of an additional strength of 500 mg to its Abbreviated New Drug Application (ANDA), from... 
From Business Wire News Releases
Amneal to Virtually Participate at the 39th Annual J.P. Morgan Healthcare Conference
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that Chirag Patel, Amneal’s Co-Chief Executive Officer and President, will present at the 39th Annual J.P. Morgan Healthcare... 
From Business Wire News Releases
Recent Challenges Demand Innovative Approaches to Surface Disinfections
- FinancialBuzz.com News Commentary 
From PR Newswire
Amneal Receives Abbreviated New Drug Application Approval for Acyclovir Cream, 5%
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal”) today announced that it has received approval for its Abbreviated New Drug Application (ANDA) from the U.S. Food and Drug Administration (FDA) for... 
From Business Wire News Releases
Amneal Reports Third Quarter 2020 Financial Results
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) announced its results today for the third quarter ended September 30, 2020. 
From Business Wire News Releases
Amneal to Report Third Quarter 2020 Results on November 6, 2020
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its third quarter 2020 financial results on Friday, November 6, 2020, prior to market open. The Company will host... 
From Business Wire News Releases
Spectrum Brands Holdings Appoints Gautam Patel and Anne S. Ward to the Board of Directors
Spectrum Brands Holdings Appoints Gautam Patel and Anne S. Ward to the Board of Directors 
From Business Wire News Releases
Company Profile for Amneal Pharmaceuticals
Amneal Pharmaceuticals, Inc. (NYSE:AMRX), headquartered in Bridgewater, NJ, is a fully-integrated pharmaceutical company focused on the development, manufacturing and distribution of generic and... 
Tags Amneal Pharmaceuticals, Inc.
From Business Wire News Releases
Amneal & PL Developments Launch Store Brand Program of Over-the-Counter (“OTC”) Diclofenac Sodium Topical Gel, 1%
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal’ or the “Company”) and PL Developments (PLD) today announced that they have commenced shipments of store brand equivalent Voltaren® Arthritis Pain Gel... 
From Business Wire News Releases
Amneal to Virtually Participate at the Morgan Stanley Global Healthcare Conference
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that members of management will participate at the Morgan Stanley Global Healthcare Conference held on September 15, 2020. The... 
From Business Wire News Releases
Amneal Receives Abbreviated New Drug Application Approval for Lidocaine Patch, 5%
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration... 
From Business Wire News Releases
Wishbone Medical Appoints Jeff George to Board of Directors
From GlobeNewswire News Releases
Amneal Reports Second Quarter 2020 Financial Results
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) announced its results today for the second quarter ended June 30, 2020. 
From Business Wire News Releases
NetworkNewsBreaks – Eastman Kodak Co. (NASDAQ: KODK) Stock Heads Skyward after Company Receives First-of-Its-Kind Government Loan
From InvestorBrandNetwork
Cosette Pharmaceuticals Appoints Seasoned Industry Executive Apurva Saraf as President and Chief Executive Officer
From GlobeNewswire News Releases
Phathom Pharmaceuticals Announces Appointment of Todd Branning as Chief Financial Officer
From GlobeNewswire News Releases
Thinking about buying stock in Unum Therapeutics, Nokia, Amneal Pharmaceuticals, Aytu Bioscience, or Niu Technologies?
InvestorsObserver issues critical PriceWatch Alerts for UMRX, NOK, AMRX, AYTU, and NIU. 
From PR Newswire
Amneal Launches Generic Fluphenazine Following ANDA Approval by FDA
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration... 
From Business Wire News Releases
Amneal to Report Second Quarter 2020 Results on August 6, 2020
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its second quarter 2020 financial results on Thursday, August 6, 2020, prior to market open. The Company will... 
From Business Wire News Releases
Amneal Reports First Quarter 2020 Financial Results
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) announced its results today for the first quarter ended March 31, 2020. 
From Business Wire News Releases
Amneal to Report First Quarter 2020 Results on May 11, 2020
Amneal to Report First Quarter 2020 Results on May 11, 2020 
From Business Wire News Releases
Amneal Launches Generic Butrans® Following ANDA Approval by FDA
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration... 
From Business Wire News Releases
Eagle Pharmaceuticals Announces Laboratory Test Results Demonstrating In Vitro Antiviral Activity of RYANODEX® (dantrolene sodium) Against Coronavirus SARS-CoV-2
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle”), a New Jersey-based pharmaceutical company, today announced that its product RYANODEX® (dantrolene sodium) for injectable suspension inhibited the... 
From Business Wire News Releases
Amneal Pharmaceuticals Moving to a Virtual Meeting Format for 2020 Annual Meeting of Stockholders
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that its 2020 Annual Meeting of Stockholders (the “Annual Meeting”) will be a virtual meeting instead of an... 
From Business Wire News Releases
State of Texas and Senator Bryan Hughes Secure a Donation of Hydroxychloroquine Sulfate from Amneal Pharmaceuticals for Texas Patients
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”), one of the largest U.S.-based generics manufacturers, and the State of Texas today announced that they are responding to the... 
From Business Wire News Releases
Thinking about buying stock in Amneal Pharmaceuticals, B2Gold, Chesapeake Energy Corp, Hepion Pharmaceuticals, or Waitr?
InvestorsObserver issues critical PriceWatch Alerts for AMRX, BTG, CHK, HEPA, and WTRH. 
From PR Newswire
Amneal Accelerates Distribution and Production of Hydroxychloroquine Sulfate to Meet Potential Needs of COVID-19 Patients Nationwide
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”), one of the largest U.S.-based generics manufacturers, today announced that it is responding to the national COVID-19 health... 
From Business Wire News Releases
Amneal Pharmaceuticals Appoints Tasos Konidaris as Senior Vice President, Chief Financial Officer
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced it has appointed Tasos Konidaris as Senior Vice President, Chief Financial Officer, effective March 12, 2020. Mr.... 
From Business Wire News Releases
Amneal Reports Fourth Quarter and Full Year 2019 Financial Results
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) announced its results today for the fourth quarter and full year ended December 31, 2019. 
From Business Wire News Releases
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.